Following my last publication on United Therapeutics (NASDAQ: UTHR ), the stock has rallied another 11% and has taken out my previous price target. Several updates have occurred since then which are in need ofEquity strategist [Bernard Holdings]. Objective view on the directional bias of markets. Technical expertise bridges the complex relationships between value drivers, capital flows and price action. Partners are represented over the cross-section of financial markets, from speculators, hedgers, long-ter ...